

## IMPACT OF AGE AT MENARCHE ON CLINICAL AND BIOCHEMICAL CHARACTERISTICS IN WOMEN WITH TYPE 2 DIABETES

CONSTANTIN IONESCU-TÎRGOVIȚE<sup>1,2</sup>, DANIELA LICĂROIU<sup>2</sup>, DENISA MARGINĂ<sup>1</sup>,  
RUCSANDRA DĂNCIULESCU MIULESCU<sup>1,2</sup> and DIANA PĂUN<sup>1,3</sup>

<sup>1</sup> “Carol Davila” University of Medicine and Pharmacy, Bucharest

<sup>2</sup> “N.C.Paulescu” National Institute of Diabetes, Nutrition and Metabolic Diseases Bucharest

<sup>3</sup> “C.I.Parhon” National Institute of Endocrinology, Bucharest

Correspondence Author: Rucsandra Dănciulescu Miulescu, Address: 5-7 Ion Movila Street, Bucharest, District 2, Postal Code 11420; Tel: 0040748134500; fax: 004021/2105575; rucsandra\_m@yahoo.com

Received August 4, 2014

**Objectives.** Previous studies have shown that early age at menarche could be associated with higher risks of type 2 diabetes, depressive symptoms, breast cancer, reproductive and cardiovascular disease. The aim of this study was to examine the association between menarche timing and the clinical and biochemical characteristics in women with type 2 diabetes (T2DM). **Material and Methods.** We evaluated 326 women aged between 44 and 60 years with confirmed T2DM-cohort 2010-2012. Data on menarche were collected using confidential self-administered questionnaire. Anthropometric, biochemical parameters were assessed. The anthropometric measurement included body mass index (BMI). The fasting plasma glucose (FPG), glycosylated hemoglobin (HbA<sub>1c</sub>), serum cholesterol, serum triglycerides, serum high-density lipoprotein (HDL)-cholesterol, insulinemia were measured. According to age at menarche, the women with type 2 diabetes were included in two groups: with menarche before 12 years (category 1) and after 12 years (category 2). **Results.** 77 women with T2DM reported age at menarche before 12 years and 249 women reported age at menarche after 12 years. Mean age at diagnosis of T2DM in the first group was  $57.18 \pm 11.50$  years and in the second group  $60.64 \pm 10.21$  years. In the first group mean BMI, FPG, HbA<sub>1c</sub>, serum cholesterol, triglycerides, HDL-cholesterol, insulinemia was  $33 \text{ kg/m}^2$ ,  $190 \text{ mg/dl}$ ,  $8\%$ ,  $16 \text{ }\mu\text{IU/ml}$ ,  $211 \text{ mg/dl}$ ,  $51 \text{ mg/dl}$ ,  $175 \text{ mg/dl}$  and in the second group the mean of the same determinations was  $32 \text{ kg/m}^2$ ,  $175 \text{ mg/dl}$ ,  $8\%$ ,  $16 \text{ }\mu\text{IU/ml}$ ,  $221 \text{ mg/dl}$ ,  $50 \text{ mg/dl}$ ,  $165 \text{ mg/dl}$ . Mean values of triglycerides and triglycerides to HDL-cholesterol ratio were significantly different between the groups. In our study, age at menarche are correlated positive with HDL-cholesterol  $r = 0.271$ ,  $p = 0.024$  in the first group and  $r = 0.179$ ,  $p = 0.008$  in the second group. Our data showed a negative correlation between age at menarche and triglycerides/HDL-cholesterol ratio ( $r = -0.177$ ,  $p = 0.009$ ) in the second group. **Conclusion.** The present study indicates that women with T2DM and age at menarche before 12 years have increased cardiovascular risk.

**Key words:** age at menarche, type 2 diabetes, obesity

### INTRODUCTION

Menarche is the first menstrual bleeding, in female humans. The timing of menarche is influenced by genetic, racial and environmental factors, especially psychosocial and nutritional factors. Age at menarche has largely decreased in Europe and seems stabilised at 13 years with 0.5 years variations between countries<sup>1</sup>. According to the Third National Health and Nutrition Examination Survey, the average age a girl begins

menstruating has declined in the last century, from 13.3 years to 12.4 years of age in United States<sup>2</sup>. Causes that may be contributing to the general trend include nutrition changes and exposures to pesticides with proestrogenic activity<sup>3,4</sup>. Age variations of menarche may be important, previous studies have shown that early age at menarche could be associated with higher risks of type 2 diabetes (T2DM), depressive symptoms, breast cancer, reproductive and cardiovascular disease<sup>5-7</sup>. The association between menarche timing and

diabetes remains unclear; the association between menarche timing with higher body mass index (BMI) and greater waist circumference may be causally responsible for the downward trend of menarche<sup>8</sup>. The aim of this study was to examine the association between menarche timing and the clinical and biochemical characteristics in women with T2DM.

## MATERIALS AND METHODS

We evaluated 326 women, aged between 44 and 60 years with confirmed T2DM (cohort 2010–2012). Data on menarche, were collected using confidential self-administered questionnaire. Anthropometric, biochemical parameters were assessed. The anthropometric measurement included body mass index (BMI). BMI was computed as a ratio of weight to the square of height ( $\text{kg/m}^2$ ). Subjects were asked to fast for 12 h before blood sampling, which was done between 8.00 and 9.00 a.m. The fasting plasma glucose (FPG), glycosylated hemoglobin ( $\text{HbA}_{1c}$ ), serum cholesterol, serum triglycerides, serum high-density lipoprotein (HDL)-cholesterol, insulinemia were measured. Insulin was evaluated using an Enzyme-linked Immunosorbent Assay (ELISA) kits,  $\text{HbA}_{1c}$  was determined by high-performance liquid chromatography (HPLC) and plasma glucose, serum cholesterol, serum triglycerides, serum HDL-cholesterol using automatic devices. According to age at menarche, the women with type 2 diabetes were included in two categories: with menarche before (category 1) and after 12 years (category 2).

### Statistical analyses

Data are presented as mean $\pm$ SD. Clinical characteristics were compared using the t Student Test. Pearson's moment-product correlation coefficients were calculated to evaluate

correlations between variables. Significance was defined at the 0.05 level of confidence. All calculations were performed using the Statistical Package for Social Sciences Software (SPSS) version 15.

## RESULTS

77 women with T2DM reported age at menarche before 12 years and 249 women with T2DM reported age at menarche after 12 years. Mean age at diagnosis of T2DM in the first group was 57 years, ranging from 23 and 81 years. In the second group, mean age at diagnosis of T2DM was 60 years ranging from 43 to 84 years. In the first group mean BMI, FPG,  $\text{HbA}_{1c}$ , serum cholesterol, triglycerides, HDL-cholesterol, insulinemia was 33  $\text{kg/m}^2$ , 190 mg/dl, 8%, 16  $\mu\text{IU/ml}$ , 211 mg/dl, 51 mg/dl, 176 mg/dl and in the second group the mean of the same determinations was 32  $\text{kg/m}^2$ , 175 mg/dl, 8%, 16  $\mu\text{IU/ml}$ , 221 mg/dl, 50 mg/dl, 165 mg/dl. Tables 1 show the characteristics for the cohort by menarche age category.

In our study age at menarche are correlated positive with HDL-cholesterol  $r=0.271$ ,  $p=0.024$  in the first group (Figure 1) and  $r=0.179$ ,  $p=0.008$  in the second group (Figure 2).

Our data showed a negative correlation between age at menarche and triglycerides/HDL-cholesterol ratio ( $r=-0.177$ ,  $p=0.009$ ) in the second group. Correlation between age at menarche and triglycerides/HDL-cholesterol ratio is shown in Figure 3.

Table 1

Characteristics of diabetic women that reported age at menarche before and after 12 years

	Category 1 (n=77)	Category 2 (n=249)	p
Age (years)	57.12 $\pm$ 11.45	60.68 $\pm$ 10.20	NS
BMI ( $\text{kg/m}^2$ )	33.20 $\pm$ 6.94	32.03 $\pm$ 8.49	NS
FPG (mg/dl)	190.62 $\pm$ 83.72	175.86 $\pm$ 80.48	NS
$\text{HbA}_{1c}$ (%)	8.65 $\pm$ 1.01	8.66 $\pm$ 1.22	NS
Basal insulin ( $\mu\text{IU/ml}$ )	16.12 $\pm$ 12.90	16.04 $\pm$ 10.42	NS
Serum cholesterol (mg/dl)	211.09 $\pm$ 54.95	221.57 $\pm$ 55.38	NS
Serum HDL cholesterol (mg/dl)	46.97 $\pm$ 13.79	48.85 $\pm$ 16.16	NS
Serum triglycerides (mg/dl)	176.39 $\pm$ 37.49	165.62 $\pm$ 10.48	$p<0.05$
Triglycerides/HDL-cholesterol ratios	4.87 $\pm$ 1.52	3.87 $\pm$ 1.06	$p<0.05$

Comparison is significant at the 0.05 level:  $p<0.05$




Figure 1. Correlation between age at menarche and HDL-cholesterol in category 1 patients.




Figure 2. Correlation between age at menarche and HDL-cholesterol in category 2 patients.




Figure 3. Correlation between age at menarche and triglycerides/HDL-cholesterol ratios.

## DISCUSSION

Previous studies have shown that age at menarche is associated with higher risk of later T2DM. In a recent issue of *Diabetes Care*, Elks CE *et al.* published a article entitled “Age at Menarche and Type 2 Diabetes Risk, The EPIC-InterAct study”. The authors evaluated the association between age at menarche and incident T2DM in 5.995 cases and they report that “Women in the earliest menarche quintile (8–11 years,  $n=2.418$ ) had 70% higher incidence of type 2 diabetes compared with those in the middle quintile (13 years,  $n=3.634$ )”<sup>9</sup>. A study performed by Dreyfus JG *et al.* analysed the age at menarche and risk of T2DM among African-American and white women in the Atherosclerosis Risk in Communities (ARIC) study<sup>7</sup>. They found that early menarche was associated with T2DM in white women but associations were attenuated after adjustment for adiposity.

In our study mean values of triglycerides and triglycerides to HDL-cholesterol ratio were significantly different between the groups. We observed a negative correlation between age at menarche and triglycerides/HDL-cholesterol ratio in the second group. It is known that high triglycerides values are associated with the presence of small, dense low-density lipoprotein (LDL) particles. The number of total and smaller LDL particles was in past studies significantly correlated with cardiovascular risk<sup>10–12</sup>. The ratio triglycerides/ HDL-cholesterol proposed by Gaziano *et al.*, is an atherogenic index that has proven to be a highly significant independent predictor of coronary heart disease<sup>13</sup>.

## CONCLUSION

The present study indicates that women with T2DM and age at menarche before 12 years have increased cardiovascular risk.

## ACKNOWLEDGEMENT

This work was supported by a grant of the Romanian National Authority for Scientific Research, CNCS-UEFISCDI, project number PN-II-ID-PCE-2011-3-0429.

## REFERENCES

1. Ong KK, Lynn Ahmed M, Dunger DB. Lessons from large population studies on timing and tempo of puberty (secular trends and relation to body size): the European trend. *Molecular and Cellular Endocrinology*, **255**:8-12, 2006.
2. Chumlea WC, Schubert CM, Roche AF, Kulin HE, Lee PA, Himes JH, Sun SS. Age at menarche and racial comparisons in US girls. *Pediatrics*, 111:110–113, 2003.
3. Kojima M, Fukuanga K, Sasaki M *et al.* Evaluation of estrogenic activities of pesticides using an in vitro reporter gene assay. *Int J Environ Health Res*, 15(4): 271-80, 2005.
4. Manabe M, Kanda S, Fukunaga K, Tsurba A, Nishiyama T. Evaluation of the estrogenic activities of some pesticides and their combinations using MtT/Se cell proliferation assay. *Int J Environ Health Res*, 209(5): 413-421, 2005.
5. Joinson C, Heron J, Lewis G *et al.* Timing of menarche and depressive symptoms in adolescent girls from a UK cohort. *The British Journal of Psychiatry*, 198: 17-23, 2011.
6. Petridou E, Syrigou E, Toupadaki N, Zavitsanos X, Willett W, Trichopoulos D. Determinants of age at menarche as early life predictors of breast cancer risk. *Int J Cancer* 68:193–198, 1996.
7. Dreyfus JG, Lutsey PL, Huxley R *et al.* Age at menarche and risk of type 2 diabetes among African-American and white women in the Atherosclerosis Risk in Communities (ARIC) study. *Diabetologia*, 55(9): 2371-80, 2012.
8. Kaplowitz PB. Link Between Body Fat and the Timing of Puberty. *Pediatrics* 121 (3): S208-S217, 2008.
9. Elks CE, Ong KK, Scott RA *et al.* Age at Menarche and Type 2 Diabetes Risk The EPIC-InterAct study. *Diabetes Care November*, 36 (11): 3526-3534, 2013.
10. Rosenson RS, Otvos JD, Freedman DS. Relations of lipoprotein subclass levels and low-density lipoprotein size to progression of coronary artery disease in the Pravastatin Limitation of Atherosclerosis in the Coronary Arteries (PLAC-I) trial. *Am J Cardiol*, 90:89–94, 2002.
11. Blake GJ, Otvos JD, Rifai N, Ridker PM. Low-density lipoprotein particle concentration and size as determined by nuclear magnetic resonance spectroscopy as predictors of cardiovascular disease in women. *Circulation*, 106:1930–1937, 2002.
12. Kuller L, Arnold A, Tracy R, Otvos J, Burke G, Psaty B, Siscovick D, Freedman DS, Kronmal R. Nuclear magnetic resonance spectroscopy of lipoproteins and risk of coronary heart disease in the cardiovascular health study. *Arterioscler Thromb Vasc Biol*, 22:1175–1180, 2002.
13. Gaziano JM, Hennekens CH, O'Donnell CJ, Breslow JL, Buring JE. Fasting triglycerides, high density lipoprotein, and risk of myocardial infarction. *Circulation*, 96:2520–5, 1997.